HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir | Zendy

Katherine A. Sutherland | Zendy; Jade Ghosn | Zendy; John Gregson | Zendy; Jean L. Mbisa | Zendy; MarieLaure Chaix | Zendy; I. Cohen Codar | Zendy; Jean François Delfraissy | Zendy; Constance Delaugerre | Zendy; Ravindra K. Gupta | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir

Author(s) -

Katherine A. Sutherland,

Jade Ghosn,

John Gregson,

Jean L. Mbisa,

MarieLaure Chaix,

I. Cohen Codar,

Jean François Delfraissy,

Constance Delaugerre,

Ravindra K. Gupta

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku365

Subject(s) - lopinavir , ritonavir , protease inhibitor (pharmacology) , lopinavir/ritonavir , virology , medicine , protease , human immunodeficiency virus (hiv) , biology , viral load , enzyme , antiretroviral therapy , biochemistry

PI susceptibility results from a complex interplay between protease and Gag proteins, with Gag showing wide variation across HIV-1 subtypes. We explored the impact of pre-treatment susceptibility on the outcome of lopinavir/ritonavir monotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research